Having read the research article published by Greenough et al,¹ regarding home oxygen use and healthcare utilisation, I was surprised to see that the fact that Abbott Laboratories had funded the research nurses for the study was only included as an acknowledgement rather than a potential conflict of interest. Abbott Laboratories have a very strong commercial interest in children with bronchopulmonary dysplasia, the subjects of this study, as they are the manufacturers of Synagis (palivizumab), an extremely costly …